ليلي

Lilly Acquires Narcolepsy Drug Developer for $7.8 Billion

Lilly, the American pharmaceutical giant, has announced its acquisition of a company specializing in the development of a drug for narcolepsy, in a deal valued at up to <strong>$7.8 billion</strong>. This move aims to expand the company's market presence and enhance its drug portfolio.